308 related articles for article (PubMed ID: 32220891)
1. Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer.
Stopsack KH; Nandakumar S; Wibmer AG; Haywood S; Weg ES; Barnett ES; Kim CJ; Carbone EA; Vasselman SE; Nguyen B; Hullings MA; Scher HI; Morris MJ; Solit DB; Schultz N; Kantoff PW; Abida W
Clin Cancer Res; 2020 Jul; 26(13):3230-3238. PubMed ID: 32220891
[TBL] [Abstract][Full Text] [Related]
2. Comparative Analysis of Genomic Alterations across Castration Sensitive and Castration Resistant Prostate Cancer via Circulating Tumor DNA Sequencing.
Fan L; Fei X; Zhu Y; Pan J; Sha J; Chi C; Gong Y; Du X; Zhou L; Dong B; Xue W
J Urol; 2021 Feb; 205(2):461-469. PubMed ID: 32897803
[TBL] [Abstract][Full Text] [Related]
3. Tissue- and Blood-derived Genomic Biomarkers for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review.
Van der Eecken K; Vanwelkenhuyzen J; Deek MP; Tran PT; Warner E; Wyatt AW; Kwan EM; Verbeke S; Van Dorpe J; Fonteyne V; Lumen N; De Laere B; Ost P
Eur Urol Oncol; 2021 Dec; 4(6):914-923. PubMed ID: 34801437
[TBL] [Abstract][Full Text] [Related]
4. Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics.
Nguyen B; Mota JM; Nandakumar S; Stopsack KH; Weg E; Rathkopf D; Morris MJ; Scher HI; Kantoff PW; Gopalan A; Zamarin D; Solit DB; Schultz N; Abida W
Eur Urol; 2020 Nov; 78(5):671-679. PubMed ID: 32317181
[TBL] [Abstract][Full Text] [Related]
5. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
Hamid AA; Gray KP; Shaw G; MacConaill LE; Evan C; Bernard B; Loda M; Corcoran NM; Van Allen EM; Choudhury AD; Sweeney CJ
Eur Urol; 2019 Jul; 76(1):89-97. PubMed ID: 30553611
[TBL] [Abstract][Full Text] [Related]
6. Genomic profiles and clinical outcomes in primary versus secondary metastatic hormone-sensitive prostate cancer.
Nizialek E; Lim SJ; Wang H; Isaacsson Velho P; Yegnasubramanian S; Antonarakis ES
Prostate; 2021 Jun; 81(9):572-579. PubMed ID: 33955569
[TBL] [Abstract][Full Text] [Related]
7. Metastatic prostate cancer is associated with distinct higher frequency of genetic mutations at diagnosis.
Al-Toubat M; Serrano S; Elshafei A; Koul K; Feibus AH; Balaji KC
Urol Oncol; 2023 Nov; 41(11):455.e7-455.e15. PubMed ID: 37838503
[TBL] [Abstract][Full Text] [Related]
8. Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer.
Gupta S; Hovelson DH; Kemeny G; Halabi S; Foo WC; Anand M; Somarelli JA; Tomlins SA; Antonarakis ES; Luo J; Dittamore RV; George DJ; Rothwell C; Nanus DM; Armstrong AJ; Gregory SG
Genes Chromosomes Cancer; 2020 Apr; 59(4):225-239. PubMed ID: 31705765
[TBL] [Abstract][Full Text] [Related]
9. Genomic Heterogeneity Within Individual Prostate Cancer Foci Impacts Predictive Biomarkers of Targeted Therapy.
VanderWeele DJ; Finney R; Katayama K; Gillard M; Paner G; Imoto S; Yamaguchi R; Wheeler D; Lack J; Cam M; Pontier A; Nguyen YTM; Maejima K; Sasaki-Oku A; Nakano K; Tanaka H; Vander Griend D; Kubo M; Ratain MJ; Miyano S; Nakagawa H
Eur Urol Focus; 2019 May; 5(3):416-424. PubMed ID: 29398457
[TBL] [Abstract][Full Text] [Related]
10. Clinical and oncologic findings of extraprostatic extension on needle biopsy in
Chen JR; Zhao JG; Zhu S; Zhang MN; Chen N; Liu JD; Sun GX; Shen PF; Zeng H
Asian J Androl; 2020; 22(4):427-431. PubMed ID: 31424026
[TBL] [Abstract][Full Text] [Related]
11. Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer.
Reimers MA; Yip SM; Zhang L; Cieslik M; Dhawan M; Montgomery B; Wyatt AW; Chi KN; Small EJ; Chinnaiyan AM; Alva AS; Feng FY; Chou J
Eur Urol; 2020 Mar; 77(3):333-341. PubMed ID: 31640893
[TBL] [Abstract][Full Text] [Related]
12. Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer.
Gupta S; Li J; Kemeny G; Bitting RL; Beaver J; Somarelli JA; Ware KE; Gregory S; Armstrong AJ
Clin Cancer Res; 2017 Mar; 23(5):1346-1357. PubMed ID: 27601596
[No Abstract] [Full Text] [Related]
13. Intraductal carcinoma of the prostate in the absence of high-grade invasive carcinoma represents a molecularly distinct type of in situ carcinoma enriched with oncogenic driver mutations.
Khani F; Wobker SE; Hicks JL; Robinson BD; Barbieri CE; De Marzo AM; Epstein JI; Pritchard CC; Lotan TL
J Pathol; 2019 Sep; 249(1):79-89. PubMed ID: 30993692
[TBL] [Abstract][Full Text] [Related]
14. Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics.
Sutera P; Van Der Eecken K; Kishan AU; Hamid A; Grist E; Attard G; Lotan T; Mendes AA; Paller CJ; Carducci MA; Ross A; Wang H; Pienta K; Feng FY; Antonarakis ES; Ost P; Song DY; Greco S; Deville C; DeWeese T; Tran PT; Deek MP
Prostate Cancer Prostatic Dis; 2022 Apr; 25(4):713-719. PubMed ID: 35013522
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns.
De Laere B; van Dam PJ; Whitington T; Mayrhofer M; Diaz EH; Van den Eynden G; Vandebroek J; Del-Favero J; Van Laere S; Dirix L; Grönberg H; Lindberg J
Eur Urol; 2017 Aug; 72(2):192-200. PubMed ID: 28104311
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 Expression in De Novo Metastatic Castration-sensitive Prostate Cancer.
Iacovelli R; Ciccarese C; Brunelli M; Bogina G; Munari E; Bimbatti D; Mosillo C; Fantinel E; Bria E; Martignoni G; Tortora G
J Immunother; 2019 Sep; 42(7):269-273. PubMed ID: 31261165
[TBL] [Abstract][Full Text] [Related]
17. Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer.
Sonpavde G; Agarwal N; Pond GR; Nagy RJ; Nussenzveig RH; Hahn AW; Sartor O; Gourdin TS; Nandagopal L; Ledet EM; Naik G; Armstrong AJ; Wang J; Bilen MA; Gupta S; Grivas P; Pal SK; Lanman RB; Talasaz A; Lilly MB
Cancer; 2019 May; 125(9):1459-1469. PubMed ID: 30620391
[TBL] [Abstract][Full Text] [Related]
18. SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity.
Boysen G; Rodrigues DN; Rescigno P; Seed G; Dolling D; Riisnaes R; Crespo M; Zafeiriou Z; Sumanasuriya S; Bianchini D; Hunt J; Moloney D; Perez-Lopez R; Tunariu N; Miranda S; Figueiredo I; Ferreira A; Christova R; Gil V; Aziz S; Bertan C; de Oliveira FM; Atkin M; Clarke M; Goodall J; Sharp A; MacDonald T; Rubin MA; Yuan W; Barbieri CE; Carreira S; Mateo J; de Bono JS
Clin Cancer Res; 2018 Nov; 24(22):5585-5593. PubMed ID: 30068710
[No Abstract] [Full Text] [Related]
19. Prognostic Value of Germline DNA Repair Gene Mutations in De Novo Metastatic and Castration-Sensitive Prostate Cancer.
Wei Y; Wu J; Gu W; Wang J; Lin G; Qin X; Dai B; Gan H; Ye D; Zhu Y
Oncologist; 2020 Jul; 25(7):e1042-e1050. PubMed ID: 32190957
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer.
Gupta S; Vanderbilt C; Abida W; Fine SW; Tickoo SK; Al-Ahmadie HA; Chen YB; Sirintrapun SJ; Chadalavada K; Nanjangud GJ; Bialik A; Morris MJ; Scher HI; Ladanyi M; Reuter VE; Gopalan A
Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):507-516. PubMed ID: 32094488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
